Seeking Alpha

SELLAS Announces Key Business Objectives for 2025

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel ...
Nasdaq

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

- 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing ...
Seeking Alpha

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

- Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens - - Overall ...
Business Insider

Sellas Life Sciences announces OS data in Cohort 3 from Phase 2 SLS009 trial

SELLAS Life Sciences (SLS) announced Cohort 3 data from the ongoing Phase 2 trial of SLS009, a highly selective CDK9 inhibitor, in relapsed/refractory acute myeloid leukemia. Patients Characteristics: ...
Nasdaq

SELLAS Life Sciences Group Reports Positive Overall Survival Data for SLS009 in r/r AML and Updates on Financial Position and Pipeline Developments

SELLAS Life Sciences Group, Inc. announced positive overall survival results from their ongoing Phase 2 trial of SLS009 (tambiciclib) in patients with relapsed/refractory acute myeloid leukemia (AML), ...
ascopubs.org

V-RULES: Real-world effectiveness and safety of CPX-351 in patients with secondary acute myeloid leukemia (AML).

Decoding immune dysregulation in AML: Insights from integrated genomic and transcriptomic analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include ...